ARTICLES LIST

Clear Search

Select the Article Source National Cancer Institute Office of Dietary Supplements National Institute on Aging Healthfinder.gov National Institute of Child Health and Human Development Centers for Disease Control and Prevention Administration for Children and Families National Institute of Environmental Health Sciences National Library of Medicine National Institute of Allergy and Infectious Diseases National Center for Complementary and Integrative Health National Institute of Neurological Disorders and Stroke NIH Senior Health National Institute of Arthritis and Musculoskeletal and Skin Diseases Health and Human Services National Institute of General Medical Sciences National Institute of Dental and Craniofacial Research National Human Genome Research Institute Food and Drug Administration Center for Tobacco Products Public Health and Medical Emergency Support for a Nation Prepared Office of Disease Prevention and Health Promotion, Healthy People National Institute on Drug Abuse National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases U S Food and Drug Administration National Institute on Deafness and Other Communication Disorders National Heart, Lung, and Blood Institute

Media ID	Source Name	Media Type	Language	Media Name	Media Description	Keywords	Keywords	Link to Article
1433	National Cancer Institute	Html	en	Genetics of Breast and Gynecologic Cancers (PDQ®)–Health Professional Version	Expert-reviewed information summary about the genetics of breast and gynecologic cancers, including information about specific genes and family cancer syndromes. The summary also contains information about interventions that may influence the risk of developing breast and gynecologic cancers in individuals who may be genetically susceptible to these diseases. Psychosocial issues associated with genetic testing are also discussed.	Pregnancy-associated breast cancer 0.506333 total breast cancer 0.488298 primary breast cancer 0.498056 BRCA1 pathogenic variants 0.493823 Prospective breast cancer 0.487994 Br J Cancer 0.484038 Int J Cancer 0.495039 individual breast cancer 0.489704 cancer risk reduction 0.475227 triple-negative breast cancer 0.516988 breast cancer decline 0.488175 ovarian cancer 0.654478 breast cancer patients 0.493005 postmenopausal breast cancer 0.500017 breast cancer risk. 0.510237 cancer risk assessment 0.501046 Natl Cancer Inst 0.80311 Ovarian Cancer Group 0.476381 BRCA1-associated breast cancer 0.507407 invasive breast cancer 0.506617 endometrial cancer 0.505116 hormone replacement therapy 0.500252 breast cancer prediction 0.489793 et al. 0.567541 BRCA2 mutation carriers 0.531322	women 0.515983 contralateral breast cancer 0.498075 early breast cancer 0.50631 early-onset breast cancer 0.489583 nonpolyposis colorectal cancer 0.483231 breast cancer family 0.518542 breast cancer diagnosis 0.495632 BOADICEA breast cancer 0.48834 PUBMED Abstract 0.498618 pathogenic variants 0.552407 Cancer Res Treat 0.576792 Breast Cancer Treatment 0.508531 epithelial ovarian cancer 0.48165 ovarian cancer risk 0.536184 breast cancer risk 0.765155 Abstract 0.613814 breast cancer survival 0.499805 breast cancer 0.946746 breast cancer mortality 0.506691 Breast cancer cluster 0.487434 family history 0.570688 breast cancer incidence 0.492239 familial breast cancer 0.49066 Breast Cancer Res 0.640001	CLICK HERE
1456	National Cancer Institute	Html	en	Vulvar Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the treatment of vulvar cancer.	lesion-type VIN grade 0.488217 radiation therapy arm 0.777718 vulvar surgical procedures 0.466679 sentinel node dissection 0.727156 Radiation Therapy section 0.586061 case series 0.468674 groin dissection study 0.616489 vulvar cancer 0.538035 positive sentinel nodes 0.479331 lymph node dissection 0.680638 sentinel node identification. 0.538816 invasive vulvar cancer 0.471336 vulvar cancer-related deaths 0.462293 radiation therapy issue 0.483522 clinically localized vulvar 0.482117 node dissection 0.932807 bloc inguinal node 0.506403 sentinel node dissections 0.642236 bilateral groin node 0.587002 Actuarial groin recurrence 0.544605 groin lymph 0.484094 pelvic node resection 0.498834 radical vulvectomy 0.489162 sentinel node 0.79935	high-grade vin 0.507503 bilateral dissection 0.465866 groin dissection arm 0.620835 invasive locoregional vulvar 0.48636 sentinel node procedures 0.539343 groin recurrence 0.545931 groin dissection 0.6467 femoral lymph node 0.521493 negative sentinel node 0.528158 negative sentinel nodes 0.475577 patients 0.605395 groin-node dissection 0.464 inguinal node dissection 0.663124 groin node dissection 0.784008 ipsilateral inguinal node 0.504912 pelvic radiation 0.458909 Node metastases 0.461128 groin node-positive disease 0.523738 groin radiation 0.532254 regional lymph nodes 0.463891 HPV 6/11-associated vulvar 0.461386 negative groin nodes 0.546977 systematic literature review 0.508112	CLICK HERE
1553	National Cancer Institute	Html	en	Childhood Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version	Expert-reviewed information summary about the treatment of childhood non-Hodgkin lymphoma.	cancer treatment 0.41722 Burkitt-like non-Hodgkin lymphoma 0.414505 panniculitis-like T-cell lymphoma 0.407586 mediastinal B-cell lymphoma 0.477834 type 0.421123 body 0.397298 childhood non-hodgkin lymphoma 0.888605 PDQ cancer information 0.389516 Non-Hodgkin Lymphoma Treatment 0.431482 clinical trial search 0.395907 B-cell non-Hodgkin lymphoma 0.444319 gamma-delta T-cell lymphoma 0.40789 clinical trials 0.596027 large cell lymphoma 0.576342 peripheral t-cell lymphoma 0.4403 clinical trial 0.545942 stem cell transplant 0.416614 Burkitt lymphoma 0.412037 anaplastic lymphoma kinase 0.405034 primary mediastinal b-cell 0.402494 diffuse large b-cell 0.419339 lymph nodes 0.504405 Pediatric-type follicular lymphoma 0.401311 large B-cell lymphoma 0.505692	radiation therapy 0.400696 childhood hodgkin lymphoma 0.422956 treatment 0.602592 Hodgkin Lymphoma Treatment 0.428936 cutaneous t-cell lymphoma 0.531706 cancer cells 0.482982 Burkitt-like lymphoma /leukemia 0.41493 HIV-related non-Hodgkin lymphoma 0.410943 certain gene changes 0.416336 Adult Non-Hodgkin Lymphoma 0.452762 recurrent lymphoblastic lymphoma 0.388804 lymphoblastic lymphoma 0.418163 follicular lymphoma 0.416701 combination chemotherapy 0.479578 non-hodgkin lymphoma 0.995932 bone marrow 0.469909 marginal zone lymphoma 0.455485 cells 0.53075 cancer clinical trials 0.407298 lymph node 0.390457 treatment options 0.51667 anaplastic large cell 0.523091 HIV-associated non-Hodgkin lymphoma 0.431952 cancer 0.673011	CLICK HERE
1559	National Cancer Institute	Html	en	Endometrial Cancer Screening (PDQ®)–Patient Version	Expert-reviewed information summary about tests used to detect or screen for endometrial cancer.	cancer treatment 0.561966 Pap test results 0.564545 ongoing clinical trials 0.564273 following PDQ summaries 0.605267 PDQ cancer information 0.713937 false-negative test result 0.559289 Uterine Sarcoma Treatment 0.562863 uterus 0.565825 Endometrial sampling 0.614718 clinical trials 0.686375 test result 0.59341 transvaginal ultrasound 0.592257 cancer information summary 0.653614 clinical trial 0.570758 test results 0.593938 breast cancer prevention 0.577475 false-positive test result 0.559048 latest published information 0.566054 PDQ® Screening 0.557798 NCI’s PDQ 0.572282 cancer symptoms 0.57367 NCI PDQ cancer 0.624163 tests 0.615659 black women 0.581998	PDQ Screening 0.598441 treatment 0.572654 cancer prevention 0.577647 screening tests 0.574176 cancer cells 0.559463 endometrial cancer screening 0.701539 Cancer Information Service 0.589993 Prevention Editorial Board 0.603972 treatment clinical trials 0.562297 National Cancer Institute 0.661886 endometrial cancer 0.979643 PDQ documents 0.56725 new treatment 0.567011 Cancer screening trials 0.628138 Cancer Care page 0.581539 PDQ database 0.570002 breast cancer 0.579583 abnormal vaginal bleeding 0.663193 non-polyposis colon cancer 0.588586 risk factor 0.558033 PDQ summary 0.615448 yearly screening 0.56313 cancer information summaries 0.594869 comprehensive cancer information 0.595413	CLICK HERE
1768	National Cancer Institute	Html	es	Perjuicios por fumar cigarrillos y beneficios para la salud al dejar el hábito	Hoja informativa que contiene una lista de algunas de las sustancias del humo de tabaco que causan cáncer y describe los problemas de salud causados por fumar y los beneficios de dejar el hábito.	Neck Cancer Epidemiology 0.422589 Mortality Weekly Report 0.414031 Human Services 0.435201 An emerging health 0.441866 Annual smoking-attributable mortality 0.414117 National Health Interview 0.418634 productivity losses—united states 0.413073 muertes prematuras 0.445781 Disease Control 0.419031 tabaco sustancias 0.451048 emerging health crisis 0.417693 promoting smoking 0.427125 Health Benefits 0.414213 Estados Unidos 0.436732 Health Behavior 0.414461 olor.  fumar kreteks 0.444861 smoking cessation after 0.432247 PubMed Abstract 0.980608 smoking cessation 0.497845 Smokeless Tobacco 0.414167 Second-hand Tobacco Smoke 0.420375 International Journal 0.420012 Smoking as 0.425711 Tobacco Research 0.428882 United States 0.434188	British Medical Journal 0.433726 early stage lung 0.412709 Causa cánceres 0.417577 causa enfermedades 0.437169 ambiente causa 0.426356 tobacco smoking 0.490331 obstructiva crónica 0.447997 tobacco aqueous pH 0.419205 Eissenberg T 0.417223 ambiente causa enfermedades 0.423335 causa inflamación 0.413975 Maziak W 0.417052 Ward KD 0.4175 systematic review 0.417039 muerte prematura 0.420666 Chronic Disease Prevention 0.413895 Andrology Prevention Weeks 0.412666 emerging health risk 0.421288 Cancer Institute 0.452427 leucemia mieloide aguda 0.439669 neck cancer 0.417125 cuánta nicotina 0.415037 Public Health Service 0.416067 New England Journal 0.413417	CLICK HERE
1836	National Cancer Institute	Html	es	Tratamiento de la leucemia mieloide aguda y otras neoplasias mieloides malignas infantiles (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento de la leucemia mieloide aguda infantil, síndromes mielodisplásicos y otras neoplasias mieloproliferativas.	frecuencia mutaciones 0.438095 LMA familiares 0.551304 leucemia eritroidea aguda 0.449843 American Academy 0.418016 Leucemia aguda eritroidea 0.453243 gen runx1t1 0.417024 neoplasias mieloides 0.421266 transient leukemia 0.421355 Sin embargo 0.442991 gen crebbp 0.417273 LMA ayuda 0.492779 necesarias mutaciones 0.436351 leucemia mielomonocítica aguda 0.45265 Panmielosis aguda 0.424398 subtipo fab 0.419671 leucemias mieloides 0.437133 Leucemia basofílica aguda 0.453074 leucemia mielógena 0.434701 Children's Oncology Group 0.430324 gen etv6 0.41685 leucemia transitoria 0.433759 reordenamiento leucemia aguda 0.452795 Leucemia megacarioblástica aguda 0.453115 Smith MA 0.431884 Leucemia aguda mielomonocítica 0.453529	gen evi1 0.417889 leucemia promielocítica aguda 0.56535 Organización Mundial 0.42957 gen mll 0.697325 células madre 0.41719 leucemia aguda 0.953312 LMA M0 0.546818 leucemia linfoblástica aguda 0.491741 SAI Leucemia 0.451225 tipo ii 0.459931 gen runx1 0.418208 Pediatr Blood Cancer 0.433879 gen cbf-beta 0.418127 M0 LMA 0.495335 leucemia monocítica aguda 0.501087 fraterno presente leucemia 0.436812 linaje mieloide 0.448127 leucemias bifenotípicas mieloides 0.422616 leucemia megacariocítica aguda 0.525006 leucemia mieloblástica aguda 0.537614 BCR-ABL1 Leucemia aguda 0.451622 leucemia mieloide aguda 0.756372 linaje linfoide 0.423692 La traslocación 0.522981	CLICK HERE
1949	National Cancer Institute	Html	es	Tratamiento del linfoma relacionado con el sida (PDQ®)–Versión para pacientes	Resumen de información revisada por expertos acerca del tratamiento del linfoma relacionado con el sida.	linfáticos afectados.ampliar linfoma 0.30069 estadio iiis+e 0.227448 células madre 0.561403 estadio iv 0.248805 siguientes elementos 0.21398 sudores nocturnos 0.287643 alto riesgo 0.208757 vía oral 0.208173 historial médico 0.211748 rayos x 0.210669 abdomen).ampliar linfoma 0.262027 estadio ie 0.284505 cáncer.ampliar aspiración 0.213287 líquido cefalorraquídeo 0.384161 punción espinal.Ampliar 0.212727 National Cancer Institute 0.208952 Instituto Nacional 0.215593 estadio iie 0.283482	PDQ Tratamiento 0.219955 segura medicamentos 0.210953 líquido incoloro 0.216453 siguientes biopsias 0.213705 estadio iiie 0.319333 siguientes problemas 0.21343 sistema nervioso central 0.917575 Physician Data Query 0.232209 cabo actividades 0.210804 ósea elabora glóbulos 0.24265 SNC).Ampliar Quimioterapia 0.221029 estadio iiis 0.541053 almacena células 0.232785 células b 0.231648 Estadio IIIE+S 0.227106 siguientes pruebas 0.212565 siguientes estadios 0.212441	CLICK HERE
2002	National Cancer Institute	Html	es	Tratamiento del feocromocitoma y paraganglioma (PDQ®)–Versión para profesionales de salud	Resumen de información revisada por expertos acerca del tratamiento del feocromocitoma y paraganglioma.	associated with 0.440801 paraganglioma hereditario sdhd 0.442898 Surg Oncol Clin 0.439027 Gimenez-Roqueplo AP 0.438768 Chatellier G 0.438739 patients with apparently 0.435891 with von hippel-lindau 0.426826 evaluation following resection 0.43956 gastric stromal sarcoma 0.435317 Carney JA 0.479643 hereditary paraganglioma 0.424404 gland scaled score 0.43937 Clin Proc 0.426209 effective treatment with 0.472522 secondary hypertension 0.431368 Neuroendocrine Neoplasias 0.453768 extra-adrenal paraganglioma 0.447147 von hippel-lindau 0.471522 feocromocitoma síndrome 0.499112 patients with 0.828258 Clin Endocrinol Metab 0.986823 Young WF Jr 0.474746 or secreting 0.439481 Servais A 0.436374 patients with metastatic 0.46137	Surg Pathol 0.438013 hypertension persistence after 0.484322 adrenal gland scaled 0.443509 Fofol I 0.439495 Feocromocitoma Opciones estándar 0.480462 Endocrinol Metab Clin 0.443246 feocromocitoma metastásico cirugía 0.494173 during pregnancy 0.424683 feocromocitoma-paraganglioma familiar tipo 0.517532 Long-term evaluation following 0.440068 endocrina múltiple tipo 0.439079 Pacak K 0.437715 Heerden JA 0.443555 with combination chemotherapy 0.426625 Intern Med 0.453092 autosomal dominant paraganglioma 0.427278 Clin Oncol 0.478285 extra suprarrenales surgen 0.434497 extra suprarrenales 0.652785 carney triad 0.424742 feocromocitoma regional cirugía 0.492979 parasimpáticos extra suprarrenales 0.431253 associated with sdhb 0.428378 familial paraganglioma 0.44151	CLICK HERE
2053	National Cancer Institute	Html	es	Vacunas contra los virus del papiloma humano	Una hoja informativa acerca de las vacunas contra los virus del papiloma humano (VPH) para prevenir infecciones con ciertos tipos de VPH, los cuales son la causa principal del cáncer de cuello del útero o cérvix.	HPV prophylactic vaccines 0.314226 hpv vaccine 0.332876 Lancet Oncology 0.308843 with preexisting infection 0.306342 Mortality Weekly Report 0.31501 bivalent hpv vaccination 0.314902 largo plazo 0.306588 Disease Control 0.307862 genital warts among 0.306064 clinical trial 0.315859 anal hpv 0.312394 Estados Unidos 0.376477 hpv vaccination 0.357231 Hariri S 0.317621 Rica Vaccine Trial 0.314539 PubMed Abstract 0.885463 human papillomavirus 0.614779 vacunas gardasil® 0.319024 Infectious Diseases 0.318629 quadrivalent hpv 0.312783 Chaturvedi AK 0.307922 BMC Infectious Diseases 0.305886 hpv infection 0.324228 Hildesheim A 0.314688 Feng Q 0.308321	among young 0.314298 papillomavirus acquisition 0.305662 United States 0.307989 alto riesgo 0.531462 Updated HPV Vaccination 0.328083 British Medical Journal 0.305646 HPV Vaccination Recommendations 0.328083 Costa Rica 0.313988 Immunization Practices 0.308391 Advisory Committee 0.307786 papillomavirus among 0.306019 infecciones persistentes.  gardasil 0.336098 9-valent human papillomavirus 0.32439 papillomavirus prophylactic vaccines 0.30978 Bocchini JA 0.307795 ¿Cuáles cánceres 0.312957 Hughes JP 0.308264 bivalent hpv 0.331056 cuello uterino 0.992097 Vaccine Safety Datalink 0.314052 genital hpv infection 0.315334 Cancer Institute 0.307587 New England Journal 0.348895 Petrosky E 0.307326	CLICK HERE
15738	National Cancer Institute	Html	en	Financial Toxicity and Cancer Treatment (PDQ®)–Health Professional Version	Expert-reviewed information summary about the risk of experiencing financial difficulty during cancer treatment.	adult cancer survivors 0.29753 cancer treatment 0.260149 study 0.333877 high out-of-pocket spending 0.29174 health insurance 0.332995 newly diagnosed cancer 0.254116 out-of-pocket cost burden 0.275794 financial hardship 0.814372 colorectal cancer patients 0.270243 colorectal cancer survivors 0.274934 economic burden 0.33821 higher out-of-pocket spending 0.308086 Support Care Cancer 0.263278 material financial hardship 0.310411 Cancer Care Outcomes 0.299421 high out-of-pocket costs 0.25691 health care 0.364957 out-of-pocket health care 0.305633 higher out-of-pocket costs 0.256873 high out-of-pocket burden 0.326935 State cancer patients 0.282656 cancer care 0.417219 personal financial burden 0.365783 lung cancer patients 0.262392	ongoing cancer care 0.28258 colorectal cancer 0.3351 cancer patients 0.489203 Clin Oncol 0.334879 comprehensive cancer center 0.290609 cancer-related financial burden 0.257868 cancer diagnosis 0.320181 later financial hardship 0.252008 Long-term financial burden 0.276409 financial distress 0.563858 out-of-pocket spending 0.410176 breast cancer survivors 0.328299 financial burden 0.630038 out-of-pocket costs 0.285058 greater financial burden 0.273818 financial toxicity 0.49873 cancer survivors 0.880073 advanced-stage cancer patients 0.289755 high financial burden 0.284717 cancer 0.949444 substantial financial hardship 0.256681 risk 0.255869 cancer history 0.289124	CLICK HERE